https://www.ncbi.nlm.nih.gov/pubmed/31796672/

2020;73(1):59-62. doi: 10.3233/JAD-190765.

Reevaluating the Microbial Infection Link to Alzheimer’s Disease.

Abstract

 Alzheimer’s disease (AD) is the most common cause of dementia. Despite substantial investment in research, there are no current effective treatments to prevent or delay the onset and development of AD and the exact molecular mechanism of AD pathogenesis is still not fully understood. Researchers have long suspected that microbial infections may play a role in AD; however, this hypothesis has been greatly overlooked for decades, only recently gaining a traction and recognition within the broad scientific community due to new overwhelming evidence on the association of various pathogenic microbes and AD.

Here, we provide our perspective on the significance of these findings, which shed light on the interplay between molecular self-assembly, neurodegeneration, and antimicrobial peptides, as well as propose an amendment to the amyloid cascade hypothesis. It is important to note that this association does not yet prove a causal link, but these reports warrant a thorough investigation into the microbial infection-AD hypothesis which might in turn deliver the elusive therapeutic target the scientific community has been so desperately searching for.

__________________

**Comment**

Perfect example of what happens when the scientific community puts blinders on – they miss things. When science becomes little more than a “good old boy club,” everyone else suffers.  Nowhere is this more evident than in Lyme/MSIDS disease research.

https://madisonarealymesupportgroup.com/2017/01/13/lyme-science-owned-by-good-ol-boys/

https://madisonarealymesupportgroup.com/2019/06/28/who-owns-the-elisa-patents/

https://madisonarealymesupportgroup.com/2019/07/16/another-propaganda-paper-by-auwaerter-more-conflicts-of-interest/ Of note, Auwaerter is on the scientific advisory committee of Diasorin, a company that makes diagnostic tests for Lyme as well as EBV  https://www.diasorin.com/en/node/8937.

This is important as many Lyme/MSIDS patients have both diseases and is a conflict of interest.  https://madisonarealymesupportgroup.com/2017/04/11/diagnosed-with-ebv-had-lyme/

In 1970 DiaSorin began the development of Infectious Disease products designed for use with ELISA technology. Since 2001 it has launched a broad array of new CLIA products, with unique infectious disease assays for use on the LIAISON® systems.

All DiaSorin Infectious Disease products are registered in compliance with the European CE mark rules with commercially available assays in the US having FDA clearance.